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ABSTRACT
All members of the Caliciviridae family of viruses produce a subgenomic RNA during infection. The subgenomic RNA typ-
ically encodes only the major and minor capsid proteins, but in murine norovirus (MNV), the subgenomic RNA also en-
codes the VF1 protein, which functions to suppress host innate immune responses. To date, the mechanism of norovirus
subgenomic RNA synthesis has not been characterized. We have previously described the presence of an evolutionarily
conserved RNA stem-loop structure on the negative-sense RNA, the complementary sequence of which codes for the viral
RNA-dependent RNA polymerase (NS7). The conserved stem-loop is positioned 6 nucleotides 3= of the start site of the sub-
genomic RNA in all caliciviruses. We demonstrate that the conserved stem-loop is essential for MNV viability. Mutant
MNV RNAs with substitutions in the stem-loop replicated poorly until they accumulated mutations that revert to restore
the stem-loop sequence and/or structure. The stem-loop sequence functions in a noncoding context, as it was possible to
restore the replication of an MNV mutant by introducing an additional copy of the stem-loop between the NS7- and VP1-
coding regions. Finally, in vitro biochemical data suggest that the stem-loop sequence is sufficient for the initiation of viral
RNA synthesis by the recombinant MNV RNA-dependent RNA polymerase, confirming that the stem-loop forms the core
of the norovirus subgenomic promoter.
IMPORTANCE
Noroviruses are a significant cause of viral gastroenteritis, and it is important to understand the mechanism of norovirus RNA
synthesis. Here we describe the identification of an RNA stem-loop structure that functions as the core of the norovirus sub-
genomic RNA promoter in cells and in vitro. This work provides new insights into the molecular mechanisms of norovirus RNA
synthesis and the sequences that determine the recognition of viral RNA by the RNA-dependent RNA polymerase.
Noroviruses, members of the Caliciviridae family of small pos-itive-sense RNA viruses, are a major cause of viral gastroen-
teritis in the developed world (1, 2). Despite their impact, norovi-
ruses remain poorly characterized, as an in-depth understanding
of the molecular mechanisms of norovirus genome translation
and replication has been hampered by the inability to culture hu-
man norovirus (3). Murine norovirus (MNV) is a model system
with which to understand the norovirus life cycle (4), as it repli-
cates in cultured cells (5) and a number of tractable reverse genet-
ics systems are available (6–9). Studies of MNV have therefore led
to a number of significant advances in the understanding of the
molecular mechanism of norovirus genome translation and rep-
lication (reviewed in reference 10).
The norovirus RNA genome typically carries three open read-
ing frames (ORFs) (11). MNV also has an additional ORF in the
region overlapping the VP1-coding region (12, 13) (Fig. 1A). All
members of the Caliciviridae family of small positive-sense RNA
viruses synthesize a shorter-than-genome-length, subgenomic
RNA (sgRNA) which directs the translation of the major and mi-
nor structural proteins, VP1 and VP2, respectively (10). The MNV
sgRNA also encodes the VF1 protein, an antagonist of the innate
immune response (12). Production of an sgRNA during the viral
life cycle is a common feature of many positive-sense RNA viruses
(14), and it is often used to control the expression of the viral
proteins.
The mechanism of calicivirus sgRNA synthesis is not well un-
derstood. Initial in vitro biochemical approaches using rabbit
hemorrhagic disease virus (RHDV) suggested that a sequence up-
stream of the first nucleotide of the subgenomic RNA is required
for sgRNA synthesis (15). This sequence acts in the complement of
the RHDV genomic RNA. Bioinformatic analysis also confirmed
the presence of evolutionarily conserved and stable RNA stem-
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loop structures upstream of the starts of the sgRNAs of calicivi-
ruses (16). Within the region coding for the viral RNA-dependent
RNA polymerase (NS7, RdRp) in all caliciviruses analyzed, an
24- to 50-nucleotide (nt) stem-loop structure on the negative-
sense genomic RNA could be predicted, precisely 6 nt 3= of the
sgRNA start site. This stem-loop structure in the MNV minus-
strand RNA will be referred to as Sla5045 (for stem-loop anti-
sense 5045). We previously observed that the stable structure
of Sla5045 is essential for the recovery of viable MNV in cultured
cells (16). In the current study, we present results consistent with
the hypothesis that Sla5045 forms the core of the norovirus sgRNA
promoter.
MATERIALS AND METHODS
Cell lines andplasmid constructs.The murine leukemia macrophage cell
line RAW264.7 was grown and maintained in Dulbecco modified Eagle
medium (DMEM) (Gibco) with 10% (vol/vol) fetal calf serum (FCS),
penicillin (100 SI units/ml), streptomycin (100 g/ml), and 10 mM
HEPES buffer (pH 7.6). Baby hamster kidney cells (BHK-21) engineered
to express T7 RNA polymerase (BSR-T7 cells, obtained from Karl-Klaus
Conzelmann, Ludwig Maximillian University, Munich, Germany) were
FIG 1 The stability of Sla5045 is required for norovirus infectivity, replication, and sgRNA synthesis. (A) A schematic of the murine norovirus (MNV) genome,
highlighting the four open reading frames and Sla5045. (B) Genetic conservation of the Sla5045 sequences on the norovirus negative-sense viral RNA. The
position of the potential norovirus subgenomic RNA initiation site is indicated with an arrow. The position of the VP1 initiation codon on the positive-sense RNA
is highlighted in bold, and sequence variation observed in different isolates is shown as bold italic. For genogroup II (GII) noroviruses, the sequence of the GII
isolate Hu/GII.4/MD-2004/2004/US is shown (DQ658413), with variation between the following isolates shown: FJ595907.1, AB447425.1, HM635151,
HM635164, JF262610.1, and JF262592. For genogroup V (GV) murine norovirus, the sequence of the CW1 isolate (DQ285629) is shown, with variation between
the following isolates displayed: JN975491 and JN975492. Note that for simplicity, only sequences showing variation in the stem-loop sequence were used in the
analysis and shown in the figure. (C) Structure of Sla5045 and the mutations introduced to generate the mutants m53 and m53r as described previously (16). In
the case of m53r, the mutations shown are in addition to those present in m53. (D) Luciferase replicon-based analysis of the effect of Sla5045 disruption.
Luciferase levels represent the mean for triplicate independent samples. (E) Virus yield after reverse genetics recovery of full-length cDNA constructs containing
either wild-type (WT) MNV, a polymerase frameshift in the NS7 (POLFS), m53, or m53r. The virus titers represent the mean values obtained at 24 h
posttransfection of viral cDNA expression constructs. The detection limit of the assay is indicated with a dotted line. In all cases where shown, error bars represent
the standard error of the mean (SEM). (F) Primer extension-mediated detection of sgRNA synthesis in MNV-infected cells (Inf) or cells transfected with capped
RNAs of WT, POLFS, m53, or m53r clones. In vitro-transcribed sgRNA was used as a positive control (sgRNA) and produces a product 3 nt longer due to the
addition of three 5= G nucleotides by T7 RNA polymerase. Note that 1,000-fold less RNA was used for the reaction using RNA from infected cells.
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maintained in DMEM containing 10% FCS, penicillin (100 SI units/ml),
streptomycin (100g/ml), and 1.0 mg/ml Geneticin (G418). All cells were
maintained at 37°C with 10% CO2.
The full-length MNV-1 cDNA clone pT7:MNV3=Rz contains the
MNV-1 genome under the control of a truncated T7 polymerase pro-
moter (7). Mutant derivatives of pT7:MNV3=RZ were made as previously
describe (7, 16). These mutations include (i) a frameshift in the NS7
region of ORF1 (pT7:MNV 3=Rz F/S), (ii) the m53 mutations to destabi-
lize the Sla5045 (pT7:MNVm53 3=Rz), and (iii) the m53r mutations to
restore the Sla5045 (pT7:MNVm53r 3=Rz). Other full-length MNV-1
cDNA clones carrying m53 mutant suppressors (m53SupA, m53SupG,
and m53SupH) in the m53 backbone construct were generated by over-
lapping PCR mutagenesis using pT7:MNVm53 3=Rz as a template. All
primer sequences used in this work and protocols will be made available
upon request. Mutant suppressors were also engineered into pT7:
MNV3=Rz, producing WTSupA, WTSupB, and WTSupC cDNA con-
structs. Additional synonymous mutations at position 4922 in the wild-
type (WT) and m53 cDNA constructs with adenylate and guanylate
substitutions were also generated by overlapping mutagenesis PCR. The
luciferase reporter-expressing MNV replicons used in this study were as
reported previously (17). Briefly, the luciferase gene was fused to VP2 in
the WT, POLF, m53, and m53r constructs and separated by the foot-and-
mouth disease virus 2A protease (FMDV 2A). The expression of the lucif-
erase reporter gene in these constructs is under the control of the MNV
TURBS sequence (18, 19). Translation of the luciferase reporter protein
occurs as a VP2 fusion protein, and the protein is cotranslationally
cleaved at the specific FMDV 2A cleavage site to release both lucifer-
ase-2A and VP2.
Sla5045Dup contains a second copy of the WT or m53 stem-loop
(Sla2) inserted outside the NS7-coding region in the intergenic region
between Orf1 and Orf2 and was used to generate constructs WT/WT,
WT/m53, m53/WT, and m53/m53 by overlapping PCR mutagenesis. A
second panel of Sla5045Dup mutant constructs was also generated based
on the m53/WT construct as detailed below.
Reverse genetics and virus yield determination. Recoveries of full-
length infectious MNV-1 cDNA clones were performed using the estab-
lished reverse genetics system (7). Typically, BSR-T7 cells were infected
with fowlpox virus expressing T7 RNA polymerase at a multiplicity of
infection (MOI) of 0.5 PFU per cell before transfection with 1g of cDNA
was carried out using Lipofectamine 2000 (Invitrogen) according to the
manufacturer’s instructions. Note that the levels of T7 RNA polymerase
normally expressed in BSR-T7 cells are not sufficient to drive MNV re-
covery. Where indicated, the RNA-mediated reverse genetics system was
used. In this case, RNA transcripts were produced using in vitro transcrip-
tion reactions with reaction mixtures consisting of 200 mM HEPES (pH
7.5), 32 mM magnesium acetate, 40 mM dithiothreitol (DTT), 2 mM
spermidine, 7.5 mM each nucleoside triphosphate (NTP) (ATP, UTP,
GTP, and CTP), 40 units of RNase inhibitor (Promega), 250 ng of linear-
ized DNA template, and 50 g/ml of T7 RNA polymerase. The reaction
mixtures were incubated at 37°C for 2 to 7 h and treated with DNase I
(New England BioLabs), and the RNA was purified by precipitation using
lithium chloride and resuspended in RNA storage solution (Ambion) (9).
Prior to transfection into BSR-T7 cells, posttranscriptional enzymatic
capping was performed on the purified RNA transcripts using a ScriptCap
system (Epicentre), according to the manufacturer’s instructions. Typi-
cally, one microgram of capped RNA was transfected using Lipofectamine
2000 according to the manufacturer’s instructions. The yield of infectious
virus was determined at 24 h posttransfection of cDNA or capped RNA,
using 50% tissue culture infectious dose (TCID50). Note that BSR-T7
cells, a BHK cell derivative, can support only a single cycle of virus repli-
cation, possibly due to the lack of a suitable receptor for virus reinfection.
RNA purification and genome copy determination. All RNA purifi-
cations from infected and transfected cells were performed using the
GenElute mammalian total RNA miniprep kit (Sigma-Aldrich) according
to the manufacturer’s instructions. RNA was quantified by spectropho-
tometry and qualitatively inspected by on agarose gels stained with
ethidium bromide.
The expression levels of genomic RNA for WT and m53SupA MNVs
were quantified using one step reverse transcription-quantitative PCR
(RT-qPCR). Viral genome copies were determined using the MESA Blue
qPCR assay (Eurogentec) performed in parallel with control RNAs of
known concentration using the primers 404F (GGAGCCTGTGATCGG
CTCTATCTTGGAGCAGG) and 491R (GCCTGGCAGACCGCAGCAC
TGGGGTTGTTGACC) to amplify the viral genomic RNA.
Where described, strand-specific RT-qPCR was performed using
tagged RT primers to detect either positive- or negative-sense genomic
RNA as previously described (20). In addition, a set of primers was de-
signed to amplify nucleotides 5473 to 5422 to facilitate the simultaneous
quantification of both genomic and subgenomic RNAs. Control RNAs for
the genomic or subgenomic RNAs, of positive- or negative-sense polarity,
were generated by in vitro transcription and used as standards to facilitate
quantification.
Western blotting. Samples for Western blot analysis were obtained by
lysing cells in radioimmunoprecipitation assay (RIPA) buffer (50 mM
Tris-HCl [pH 8.0], 150 mM NaCl, 1 mM EDTA, 1% Triton X-100, and
0.1% SDS). Protein concentration in the lysates were quantified using the
bicinchoninic acid (BCA) protein assay (Pierce). Equal amounts of pro-
tein per sample were separated by SDS-PAGE and transferred to a poly-
vinylidene fluoride (PVDF) Immobilon-P transfer membrane (Millipore)
for detection using enhanced chemiluminescence (ECL) reagents by
semidry transfer. The blocking buffer (PBST) contained 0.1% Tween 20 in
phosphate-buffered saline (PBS) containing 5% (wt/vol) milk powder
and the rabbit anti-MNV NS7 or VP1 serum. Antibody binding was de-
tected using a horseradish peroxidase-conjugated secondary antibody
(source). The signal was detected with an enhanced chemiluminescence
kit (ECL; Amersham Biosciences).
Luciferase reporter assay. Cell lysates used to detect luciferase activity
were prepared by lysing the transfected cells in 1 reporter lysis buffer
(Promega) according to the manufacturer’s instructions. The protein
concentration in each lysate was standardized, and total protein (30 g)
from each cell lysate was analyzed. The luciferase assays used a 1:500
dilution of coelenterazine (Promega) in PBS as a substrate. Luciferase
activity was measured in an autoinjector luminometer (FLUOstar Omega;
BMG Labtech).
Northernblot assay.Total RNAs were purified from infected cells and
denatured by glyoxylation according to the manufacturer’s instructions
(Ambion). Denatured RNAs along with the relevant control RNA gener-
ated by in vitro transcription to produce full-length MNV genomic and
subgenomic RNAs of both polarities were separated by agarose electro-
phoresis. Denatured RNAs were transferred to Hybond N nylon mem-
branes using mild alkaline conditions and the viral RNA detected using
the NorthernMax Northern blotting system (Life Technologies). RNA
probes used to detect the positive- and negative-sense viral RNAs were
generated by incorporating [32P]UTP or CTP using the Maxiscript in vitro
labeling system according to the manufacturer’s instructions (Ambion).
The RNA probe used to detect the negative-sense viral RNA consisted of
nt 1 to 200 of the positive-sense sgRNA, whereas the positive-sense viral
RNA was detected using a probe complementary to nt 7161 to 7382.
5= RACE. Total RNA preparations were subjected to cDNA synthesis
using a reverse primer complementary to sequences 700 bases down-
stream (on positive polarity) of Sla5045. The resulting cDNAs were
treated with RNase to degrade the viral RNA template. The purified
cDNAs were then used as a template for rapid amplification of cDNA ends
(RACE) assay using 5= RACE according to the manufacturer’s instruc-
tions (Life Technologies). Purified cDNAs were first subjected to the 3=-
end poly(C) tailing reaction catalyzed by terminal transferase, followed by
PCR using an anchor primer that anneals to the poly(C) 3= end of cDNA
and the MNV-specific reverse primer. Sequences of the PCR products
were determined using the BigDye Terminator kit and analyzed using the
Vector NTI software (Invitrogen).
Yunus et al.
1220 jvi.asm.org January 2015 Volume 89 Number 2Journal of Virology
 o
n
 January 27, 2016 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
Primer extension analysis. Primer extension analysis was performed
on RNA isolated from either infected cells or cells transfected with in
vitro-transcribed capped RNAs generated from MNV cDNA-containing
clones. The [-33P]ATP-labeled primer 5129R (GGTTGAATGGGGACG
GCCTGTTCAACGG) was annealed to 10 g of total RNA and extended
using Superscript III according to the manufacturer’s instructions (Life
Technologies). Reactions were stopped by the addition of formamide-
containing dye, followed by separation on 6% urea-PAGE. The extended
products were visualized following exposure to autoradiography film and
compared to samples isolated from infected cells and control RNA pro-
duced by in vitro transcription.
Recombinant RdRp expression and purification. The cDNA encod-
ing MNV NS7 (nt 3537 to 5069) was subcloned in pET-15b. The construct
contains an N-terminal six-histidine tag to facilitate protein purification.
The plasmid expressing MNV NS7 was transformed into Escherichia coli
Rosetta cells, which were grown at 37°C until the optical density at 600 nm
(OD600) was between 0.6 and 0.8. Isopropylthiogalactoside was added to a
final concentration of 1 mM to induce protein expression for 16 to 18 h at
16°C. The cells were harvested by centrifugation and resuspended in 40 ml
lysis buffer (100 mM Tris-Cl [pH 7.9], 300 mM NaCl, 10% glycerol, 15
mM imidazole, 5 mM -mercaptoethanol, 0.1% Triton X-100, protease
inhibitor cocktail [Sigma]). The recombinant protein was purified with
Ni-nitrilotriacetic acid (NTA) (Qiagen) according to the manufacturer’s
instructions. The eluted protein was dialyzed in buffer containing 100
mM Tris-Cl (pH 7.9), 300 mM NaCl, 10% glycerol, and 5 mM-mercap-
toethanol and stored in aliquots at80°C.
Recombinant GII.4 NS7 was expressed and purified as previously de-
scribed (17). Briefly, E. coli Top 10 cells transformed with pBAD GII.4NS7
plasmid were cultured at 37°C until an OD600 of around 0.6 was reached.
L-Arabinose was added to a final concentration of 0.02% to induce protein
expression. The cells were grown at 37°C for 5 h and then harvested and
suspended in lysis buffer (50 mM HEPES [pH 7.9], 150 mM NaCl, 10%
glycerol, 10 mM imidazole, proteinase inhibitor cocktail [Sigma]). The
protein was purified by Talon metal affinity resin (Clontech Laboratories)
and the eluted protein dialyzed in buffer containing 100 mM Tris-Cl (pH
7.9), 300 mM NaCl, 10% glycerol, and 5 mM -mercaptoethanol and
stored in aliquots at80°C. All recombinant proteins were quantified by
using the Bradford method followed SDS-PAGE and staining with Coo-
massie brilliant blue to examine their purity.
RNA synthesis assay. RNA synthesis by the recombinant RdRps was
assayed as previously described (21) with minor modifications. The 20-l
reaction mixture contained 20 mM sodium glutamate (pH 7.4), 12.5 mM
dithiothreitol, 4 mM MgCl2, 1 mM MnCl2, 0.5% (vol/vol) Triton X-100,
0.2 mM GTP, 0.1 mM ATP and UTP, 3.3 nM [	-32P]CTP (MP Biomedi-
cals), 50 nM MNV RNA template, 250 nM recombinant RdRp. The reac-
tion mixture was incubated at 30°C for 2 h, and then the reaction was
stopped by the addition of EDTA (pH 8.0) to final concentration of 10
mM. The RdRp products were subjected to electrophoresis in a 24% poly-
acrylamide gel containing 7.5 M urea and 0.5Tris-borate-EDTA (TBE).
The radiolabeled RNA products were visualized and quantified by us-
ing a PhosphorImager (Typhoon 9210; Amersham Biosciences) and
ImageQuant software.
RESULTS
The stability of Sla5045 contributes to norovirus infectivity and
subgenomic RNA synthesis. Sequence analyses of published no-
roviruses genomes indicate that the stem-loop sequence of
Sla5045 is highly conserved (Fig. 1B and data not shown). Several
positions in genogroup II (GII) or GV, representing human and
murine noroviruses, respectively, appear to show some variation
in sequence, although in all cases a complex stem-loop structure is
retained (Fig. 1B). We initially sought to test the functional signif-
icance of the stability of Sla5045. Three nucleotide substitutions
were introduced into the MNV genome, resulting in a construct
named m53 (Fig. 1C). m53 was previously shown to have a se-
verely reduced recovery of infectious virus (16). However, it was
not determined whether the inability to produce detectable virus
was due to a defect in RNA encapsidation, in sgRNA production,
or both. To further validate the role of Sla5045 in the norovirus life
cycle and to examine whether the m53 mutations affect viral RNA
synthesis, we inserted the previously described m53 substitutions
into the MNV luciferase replicon Mflc-R (17). The replicon con-
sists of a full-length MNV genome expressing a Renilla luciferase-
FMDV 2A peptide-VP2 fusion protein in the VP2-coding region.
Transfection of BSRT7 cells with enzymatically capped, in vitro-
transcribed RNA from the Mflc-R cDNA leads to luciferase ex-
pression in the absence of infectious virus production. As lucifer-
ase is expressed from ORF3 and expression occurs via a conserved
termination-reinitiation mechanism of translation at the transla-
tional termination signal of ORF2 (18, 19), it functions as a highly
sensitive marker for the production of sgRNA. The introduction
of the m53 mutations resulted in luciferase levels similar to those
for a replication-defective replicon containing a frameshift in the
NS7-coding region (Fig. 1D). A construct containing mutations
compensatory to m53, named m53r (Fig. 1C), that restored the
stability of Sla5045 was found to restore luciferase expression lev-
els to nearly the level of the WT MNV replicon (Fig. 1D). The
introduction of m53r mutations also resulted in the recovery of
infectious virus (Fig. 1E). These data are consistent with the
hypothesis that Sla5045 plays a role in viral RNA synthesis and
does not simply affect a late stage in the viral life cycle such as
encapsidation.
We analyzed the production of sgRNA in cells transfected with
capped RNAs of m53 and m53r using a primer extension assay. A
radiolabeled primer complementary to nucleotides 5121 to 5129
was annealed to RNA isolated from transfected cells and extended
using reverse transcriptase, generating a product of 105 nt corre-
sponding to the start of the sgRNA. While sgRNA was detected in
infected or cells transfected with WT RNA, it was absent in m53
but restored to almost wild-type levels in m53r (Fig. 1F). Taken
together, these data confirm that the stability of Sla5045 contrib-
utes to MNV sgRNA synthesis, as well as that the production of
luciferase and the presence of infectious virus correlate with
sgRNA synthesis.
Rapid reversion and suppression of Sla5045 disruption oc-
cur in cell culture. The replication cycles of many positive-sense
RNA viruses are error prone, and the reversion or phenotypic
suppression of the introduced mutations can occur even with low
levels of viral replication. Such reversion or suppression can be-
come apparent after repeated passage of samples obtained by re-
verse genetics recovery. To examine whether it was possible to
isolate revertants or suppressors of MNV containing the m53 mu-
tations, named MNVm53, clarified tissue culture supernatants
from three independent reverse genetics recoveries were serially
passaged in RAW264.7 cells until cytopathic effect (CPE) was ob-
served. In all cases CPE was observed after 3 passages in permissive
cells. Passages performed with similar samples obtained using the
POLFS construct failed to result in CPE. Individual viral isolates
were isolated by limiting dilution, and the sequence of the NS7-
coding region was determined. In all cases we observed additional
changes in either Sla5045 or sequences elsewhere in the viral ge-
nome (Fig. 2). In total, we identified 12 different independently
derived viable viruses that could be divided into two groups: phe-
notypic revertant mutants (Rev 1 to 9) that contained mutations
Norovirus Subgenomic RNA Synthesis
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that phenotypically restored the base pairing of Sla5045 and sup-
pressor mutants (SupA to -C) that retained the m53 mutations
but had additional changes elsewhere. All Rev isolates contained
mutations that appeared to restore the stability of Sla5045 by ei-
ther reintroducing the WT sequence (Rev 2 to 6 and 8) or intro-
ducing a stabilizing mutation on the opposite side of the stem (Fig.
2B). In contrast the suppressor mutants retained the m53 muta-
tions but had additional changes in the NS7-coding region. Of the
three Sup mutations identified, SupA and SupC had synonymous
mutations that did not alter the corresponding amino acid (data
FIG 3 Characterization of m53 suppressor mutations. (A) Virus yield following reverse genetics rescue of cDNA constructs containing WT or m53 MNV cDNA
with or without the additional second-site mutations as detailed in Fig. 2A. Reverse genetics recovery was performed as described in Materials and Methods and
then the virus yield at 24 h posttransfection determined by TCID50. The dotted line represents the detection limit of the assay, with error bars representing the
SEM. (B to D) Single-step growth curve analysis of m53SupA replication in comparison to that of WT MNV. RAW264.7 cells were infected at a multiplicity of
infection of 4 TCID50 per cell and samples harvested at the indicated times postinfection. Infectious virus was released by freeze-thawing and titrated. (B)
Infectious virus titers; (C) protein expression levels of NS7 and VP1; (D) viral genomic RNA levels. In panel D, only samples from the exponential growth phase
are shown. Error bars represent the SEM.
FIG 2 Sequence analysis of m53 phenotypic revertants and second-site suppressor mutants. (A) Positions mutated in the m53 mutant are shown in bold, with
any changes observed in the phenotypic revertants highlighted in gray. The nucleotide sequences shown are for the negative-sense RNA genome. An asterisk
indicates that the identified sequence change results in a coding change in the viral NS7 protein (T439A). Revertant mutants are defined as those that
phenotypically restore the base pairing of Sla5045. Suppressors are those that retain the mutations in Sla5045 but have additional mutations outside the region.
(B) Location of reversion mutations isolated after repeated passage of m53 in cell culture. Note that the suppressor mutations are not shown, as they lie outside
the region containing Sla5045.
Yunus et al.
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not shown), while SupB resulted in a threonine-to-alanine substi-
tution at residue 439 of NS7.
Both coding and noncoding suppressor mutations in the
NS7-coding region complement thedefect inMNVm53.To con-
firm that SupA to -C can suppress the defect in MNVm53 repli-
cation, individual mutations were introduced into full-length
cDNA clones from WT MNV or m53 and the effect on virus re-
covery examined in BSRT7 cells. The BHK-derived BSRT7 cells
are permissive for viral replication but not viral infection, with the
viral yields being indicative of a single cycle of viral replication (7).
All three suppressor mutations were viable in the m53 back-
ground, confirming their ability to restore the replication defect of
MNVm53 (Fig. 3A). SupA, with an A4922G substitution on the
negative-sense RNA, was consistently better at restoring the rep-
lication defect of MNVm53 than SupB or -C, improving viral
yields by more than 10-fold compared to the virus with both the
m53 and either the SupB or SupC mutations. All three Sup muta-
tions were also viable in the WT cDNA background, with SupA
producing viral yields that were comparable to those for WT
MNV by 48 h after transfection (Fig. 3A and B). Sequence analysis
indicated that all viruses were stable for at least three passages in
cell culture (data not shown). Given that SupA and -C had synon-
ymous mutations, these results strongly suggest that the suppres-
sion of the m53 defect acted on the viral RNA.
The replication of MNVm53SupA was further characterized by
one-step growth curve analysis (Fig. 3B to D). The production of
infectious virus (Fig. 3B), viral protein (Fig. 3C), and viral RNA
(Fig. 3D) were all reduced in MNVm53SupA compared to WT
MNV. The mutation introduced in SupA results in a silent
U4922C mutation on the positive-sense RNA (Fig. 4A). This po-
sition corresponded to an alanine at codon 461 in NS7 and enables
additional silent mutations to be introduced. We examined
whether substitutions to the other three nucleotides at this posi-
tion would also suppress the m53 defect as well as affect WT MNV.
All 4 mutations were well tolerated in a WT MNV background,
whereas only the substitutions equivalent to SupA, A4922G on the
minus strand or A4922U on the minus-strand RNA, restored rep-
lication in the MNVm53 backbone (Fig. 4B). All viable viruses
could be repeatedly passaged in cell culture, and the sequences
introduced remained stable (data not shown). These data suggest
that there is a sequence-specific requirement for the ability of po-
sition 4922 to suppress the defect in MNVm53.
Sla5045 function at a different location in theMNV genome.
Due to the location of Sla5045 in the NS7-coding region, muta-
tional analysis was limited to synonymous changes that do not
alter the NS7 protein sequence. To facilitate additional mutational
analysis, we added a second copy of Sla5045, named Sla2, after the
ORF1 termination codon. Sla2 is located within a noncoding in-
tragenic region introduced between the coding sequences of NS7
and VP1 in construct Sla5054Dup (Fig. 5A). The cDNA of
Sla5045Dup was engineered to contain either a WT or m53 ver-
sion of Sla5045 or in the region containing Sla2. In vitro-tran-
scribed and capped RNA was then transfected into cells and the
effect on virus yield examined at 24 h posttransfection. RNA-me-
diated reverse genetics recovery was used to significantly improve
the yield of recovered viruses and to enhance our ability to detect
viruses that replicate poorly. As expected, RNA generated from
the WT MNV cDNA clone resulted in 105 infectious units per
ml, whereas m53 and a polymerase mutant failed to produce any
detectable virus (Fig. 5B). Sla5045Dup containing Sla5045 WT/
Sla2 WT (WT/WT) reproducibly yielded viable virus, whereas the
WT/m53 construct, containing a mutated Sla2, did not (Fig. 5B).
In constructs where Sla5045 contained the m53 mutations, a WT
Sla2 restored replication, whereas an m53 Sla2 did not (Fig. 5B).
These results demonstrate that only stem-loop sequences posi-
tioned at Sla2 function as sgRNA promoters in the context of the
Sla5045Dup cDNA constructs. Importantly, however, given that
the yield of virus obtained from the Sla5045Dup constructs
WT/WT and m53/WT was significantly lower than that of the WT
virus (Fig. 5B), it appears that the sgRNA promoter functions less
well in the Sla2 position.
Western blot analysis was used as an indirect measure of viral
RNA transfection efficiency, as we have previously observed that
viral antigen expression after transfection of RNA is due to trans-
lation of the capped RNA only and not due to viral replication (9).
Similar levels of the NS7 protein were detectable in all cases, al-
though the Sla5045Dup construct that contained Sla5045 WT/
Sla2 WT produced a protein detected by the anti-NS7 antisera
with higher molecular weight (identified by an asterisk in Fig. 5B).
We suspect that this was due to the insertion of an additional
stable stem-loop structure in close proximity to the NS7 stop
codon resulting in suppression of translational termination, as
this has been widely documented in the literature (reviewed in
FIG 4 Sequence changes at position 4922 can compensate for a defect in
Sla5045. (A) Schematic illustration of the region of the MNV genome mutated
in m53 and m53SupA. The sequence of the region shown is represented in the
positive polarity to highlight the NS7 reading frame, with the negative-polarity
sequence shown below. The amino acids encoded by the region are high-
lighted, as well as the position of the SupA mutation (in italics) and the muta-
tions introduced in m53. (B) Virus yield following reverse genetics rescue of
cDNA constructs containing wild-type (WT) or m53 MNV cDNA with vari-
ous changes at position 4922. Note that the nucleotide sequences shown rep-
resent the sequence of the antisense RNA genome, with G representing the
previously isolated SupA suppressor mutation and A representing the nucle-
otide present in the wild-type cDNA construct. Reverse genetics recovery was
performed as described in Materials and Methods and then the virus yield at 24
h posttransfection determined by TCID50. The dotted line represents the de-
tection limit of the assay, with error bars representing the SEM.
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reference 22). This hypothesis is also supported by the absence of
the extended product when the Sla5045 was disrupted by the in-
troduction of the m53 mutations. The lack of NS7 expression in
the POLFS polymerase mutant was due to the introduction of a
frameshift mutation, leading to the production of a truncated NS7
protein that is rapidly degraded (9).
Although the titers of the Sla5045Dup viruses recovered were
low, some of the introduced mutations were stable and could be
passaged in cell culture, indicating that they are viable (Fig. 5C).
Sequence analysis and 5= RACE confirmed that the introduced
mutations were stable for up to 3 passages in cell culture and that
the start of the sgRNA produced during authentic norovirus rep-
lication in cell culture is position 5052, as has been predicted pre-
viously (Fig. 5D) (4).
The sequence, positioning, and stability of Sla5045 are essen-
tial for norovirus replication. Our data indicate that Sla5045 is
essential for norovirus replication and that its function can be
complemented by an additional copy in cis in a noncoding region
upstream of the capsid-coding sequence. To examine the se-
quence requirement further, we made constructs that contained a
mutated m53 within the NS7-coding region along with various
mutant forms in the second copy present in the noncoding region.
The construct Sla5045Dup m53/Sla2 m53r contained the m53r
derivative of Sla5045, which is predicted to compensate for the
disrupted base pairs in m53 (Fig. 6A). As expected, Sla5045Dup
m53/Sla2 m53r produced viable virus after reverse genetics recov-
ery (Fig. 6B). The resultant virus could be passaged in cell culture
(Fig. 6C) and stably maintain both copies of Sla5045 (data not
shown). In contrast, Sla5045Dup m53/Sla2 WT  8, where the
spacing between the stem-loop and the predicted initiation site of
the sgRNA was increased from 6 to 8 nt, was not viable. Significant
alterations to the base stem sequences (Sla5045Dup m53/Sla2
U
FIG 5 Duplication of Sla5045 enables mutagenesis in a noncoding context. (A) Schematic illustration of the reconstruction of Sla5045Dup stem-loop dupli-
cation constructs. The position of the authentic Sla5045 on the antisense RNA genome is shown, and the introduced additional Sla5045 is shown as Sla2. For
simplicity, only wild-type copies of the stem-loop are shown. The positions of the NS7 stop and VP1 start codons on the corresponding positive-sense viral RNA
are also shown for reference. (B) Virus yield following reverse genetics rescue of capped in vitro-transcribed RNA of wild type (WT), polymerase frameshift
(POLFS), m53, or Sla5045 stem-loop duplication (Sla5045Dup) constructs. The Sla5045Dup constructs are shown using the nomenclature copy1/copy2 as
described in the text. Reverse genetics recovery was performed as described in Materials and Methods using in vitro-transcribed, enzymatically capped RNA and
the virus yield at 24 h posttransfection determined by TCID50. A Western blot analysis for NS7 expression is shown below the virus yield data. The asterisk
indicates a greater-than-full-length NS7 product observed in cells transfected with SLa5045Dup WT/WT. (C) Virus yield assay following a single passage of virus
recovered following RNA transfection of wild-type MNV (WT) or various Sla5045 stem-loop duplications. The dotted line represents the detection limit of the
assay, with error bars representing the SEM. (D) 5= RACE analysis of WT MNV or Sla5045 stem-loop duplications. Viral RNA was isolated from infected cells and
subjected to 5= RACE analysis. Samples were prepared with or without reverse transcription (RT) and then subjected to PCR as described in Materials and
Methods. The wild-type MNV virus was included as a control. Samples were then sequenced and aligned as shown. The lowercase poly(G) tract is introduced as
a result of the 5= RACE methodology.
Yunus et al.
1224 jvi.asm.org January 2015 Volume 89 Number 2Journal of Virology
 o
n
 January 27, 2016 by University of Birm
ingham
http://jvi.asm.org/
D
ow
nloaded from
 
SL or SL) or disruption of the top stem sequence (Sla5045Dup
m53/Sla2 S2) also prevented replication (Fig. 6A to C). In con-
trast, the introduction of two nucleotide changes in the terminal
loop region of Sla5045 in the construct Sla5045Dup m53/Sla2
TL-Dis had no effect on the ability of Sla5045 to complement the
defect in the m53 mutant backbone and did lead to the production
of viable virus (Fig. 6A to C).
Sla5045 functions as a template for the norovirus RNA poly-
merase NS7 in vitro. Results from characterization of Sla5045 are
all consistent with the hypothesis that Sla5045 forms the core of
the promoter for MNV sgRNA synthesis and is used to direct
sgRNA synthesis. However, it is unclear whether it functions di-
rectly in RNA synthesis. To determine whether this is the case, we
examined whether RNAs that contain Sla5054 can direct RNA-
dependent RNA synthesis by the recombinant MNV NS7 protein
in vitro (Fig. 7A). An RNA containing Sla5045 with a 5= overhang
that contains the initiation nucleotide 5052 was chemically syn-
thesized in an RNA that we termed the MNV proscript (MNVPs).
The term proscript is used to denote that the RNA contains both a
putative promoter and the template sequence (23) (Fig. 7B). If the
MNV proscript directs accurate initiation of RNA synthesis from
nt 5052, an 11-nt product should result. Based on comparison
with RNAs of known lengths, the products of MNVPs were 11 nt
in length. We also observed a 10-nt RNA that is presumed to be a
premature termination product that has been previously observed
with other recombinant RdRps (Fig. 7C) (24). To ascertain that
the RNA was initiated from the expected cytidylate at nt 5052,
we tested an RNA, named NMV IM, that is identical to MNVPs
except that nt 5052 was replaced with an adenylate. IM failed to
direct the synthesis of either the 10- or 11-nt RNA product (Fig.
7C). These data confirm that Sla5045 can accurately direct de
novo initiation of the norovirus sgRNA synthesis.
In the in vitro RNA synthesis reactions, we also detected an
RdRp product of ca. 60 nt, longer than the input proscript. This
RNA is likely formed by viral RdRp using the 3=-terminal nucleo-
tide of the template RNA to form a primer-extended product (25).
This activity is common to numerous viral RdRps (26, 27). Nota-
bly, IM generated a higher abundance of the primer-extended
RNA products than did MNVPs. Since de novo-initiated RNA
product generated from MNVPs was more abundant that those
from primer extension, we conclude that the recombinant MNV
RdRp has a propensity for de novo-initiated RNA synthesis from
the MNV sgRNA.
To examine further whether the MNV Sla5045 can direct geno-
type-specific RNA synthesis by the MNV RdRp, we performed in
vitro RNA synthesis reactions with proscript containing the com-
parable sequence from a human GII.4 norovirus, named GII.4Ps
(Fig. 7B). Accurate de novo-initiated RNA synthesis from GII.4Ps
FIG6 Mutational analysis of Sla5045 in a noncoding context. (A) Schematic illustration of Sla5045 mutations characterized in the Sla5045Dup cDNA backbone.
Sla5045 is shown in the 3=-5= direction, with the site of subgenomic RNA initiation shown in italics. Mutations introduced are highlighted in bold. (B) Virus yield
following reverse genetics rescue of capped in vitro-transcribed RNA of WT, polymerase frameshift (POLFS), m53, or Sla5045 stem-loop duplication
(Sla5045Dup) constructs. The Sla5045Dup constructs are shown using the nomenclature copy1/copy2 as described in the text. Reverse genetics recovery was
performed as described in Materials and Methods using in vitro-transcribed, enzymatically capped RNA and the virus yield at 24 h posttransfection determined
by TCID50. (C) Virus yield assay following a single passage of virus recovered following RNA transfection of the various Sla5045 stem-loop duplications. The
dotted line represents the detection limit of the assay, with error bars representing the SEM.
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should give rise to an 8-nt product (Fig. 7D). The recombinant
MNV RdRp did produce RNAs of 8 nt and 7 nt from GII.4Ps (Fig.
7D). However, in more than six independent assays, the amount
of the RNA product was 27% of the amount produced from the
MNV RdRp. In contrast, the recombinant GII.4 RdRp produced
more than 30-fold the amount of products from the GII.4Ps than
from the MNVPs (Fig. 7D). The MNV RdRp reproducibly pro-
duced a reduced amount of the primer extension product from
the GII.4Ps (13%) (Fig. 7D). Furthermore, the GII.4 RdRp also
produced a reduced level of primer extension products from the
MNVPs (Fig. 7D). These results suggest that MNV RdRp can spe-
cifically recognize the MNVPs.
Negative-sense subgenomic RNA is produced during MNV
replication. The presence of Sla5045 on the negative-sense
genomic RNA and the ability of Sla5045 to function in vitro as a
template for priming by the RdRp would fit with the hypothesis
that MNV uses a process of internal initiation for the generation of
sgRNA. However, negative-sense sgRNA is readily detected in
cells infected with feline calicivirus (FCV) (28) and in Norwalk
virus replicon-containing cells (29). Northern blot and strand-
specific RT-qPCR analysis of RNA isolated from MNV-infected
cells also confirmed the presence of a negative-sense sgRNA inter-
mediate (Fig. 8A). While we observed similar levels of negative-
sense genomic RNA and sgRNA produced in infected cells, the
levels of sgRNA were typically
26-fold higher than the genomic
RNA levels (Fig. 8B), fitting with previous observation on FCV
and Norwalk virus (28, 29). These data are consistent with the
hypothesis that newly synthesized MNV sgRNA may function as a
template for further rounds of replication via a negative-sense
sgRNA intermediate.
DISCUSSION
In this study, we used a combination of genetic and biochemical
approaches to characterize a stem-loop RNA sequence that we
predicted to be the MNV sgRNA promoter. A mutant MNV that
has substitutions that disrupted the predicted secondary structure
of the stem-loop was poorly infectious, while nucleotide substitu-
tions that restored the stem-loop structure allowed the virus to
regain infectivity. Suppressor mutations found after repeated pas-
sages in cell culture also had restored Sla5045 structure, although
additional suppressor mutations were also isolated outside the
Sla5045. Examination of a second copy of Sla5045 in a noncod-
FIG 7 Sla5045 can direct the initiation of RNA synthesis by the MNV RdRp in vitro. (A) Recombinant RdRps from MNV and the human GII.4 norovirus used
in this study. The RdRps was expressed and purified as described in Materials and Methods. The gel images were from SDS-PAGE and Coomassie blue staining.
(B) Schematics of the synthetic MNV proscript, MNVPs, and the GII.4 RNA proscript, GII.4Ps, used for the in vitro RNA synthesis assays. The initiation
nucleotide used to initiate MNV subgenomic RNA synthesis is in bold and denoted with an arrow. A proscript containing a mutated initiation site named IM is
used to control for specificity. (C) Denaturing PAGE analysis of in vitro RNA synthesis assays using the MNV NS7 with either MNVPs or the initiation mutant
(IM). The positions of primer extension (PE) and de novo initiation products are highlighted. The lengths of the RNAs were assigned by comparison to RNAs of
8 to 51 nt that were labeled at the 5= terminus with 32P. (D) Virus genotype-specific RdRp-proscript interaction results in a higher level of RNA-dependent RNA
synthesis. The results are representative of six independent experiments.
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ing region of the MNV genome revealed that the stem-loop
structure functions in cis. Using purified recombinant viral
RdRp, we demonstrated that an RNA containing Sla5054 can
direct the genotype-specific initiation of RNA synthesis from
Sla5045.
A change in the codon of viral RdRp NS7 was found in SupB,
which suppressed the changes in m53. Further analysis of this
nucleotide position indicated that the effect was mediated in a
noncoding context, as changing this codon (ACU) to GUU to
code for valine, or to GAU to code for aspartic acid, also restored
replication to m53 (data not shown). There are several explana-
tions for our ability to isolate second-site suppressor mutations
outside Sla5045. The first is that Sla5045 may form higher-order
RNA structures with other regions of the viral genome, including
the positions identified as second-site suppressors, and that the
second-site suppressors stabilize these interactions. Our bioinfor-
matic analysis has failed to identify any obvious interactions be-
tween the regions (data not shown). However, accurate predic-
tions of long- or medium-range RNA-RNA interactions are not
currently available, and we cannot at this point rule out that long-
range RNA-RNA interactions contribute to Sla5045 function. In
addition, the introduction of the m53 mutations could result in
promiscuous base pairing of Sla5045 with other sequences flank-
ing the start of the sgRNA. The suppressor mutations then func-
tion to disrupt the “off-target” RNA-RNA interactions, favoring
the restoration of the Sla5045 structure. Distinguishing between
these two possibilities will be challenging; however, our observa-
tion that the addition of Sla5045 to the 3= end of minigenome RNA
with a reporter gene in the antisense orientation is not sufficient to
drive RNA synthesis and reporter gene expression in infected cells
(data not shown) suggests that additional RNA sequences may
contribute to RNA synthesis directed by a core promoter that
consists of Sla5045.
The production of an sgRNA is conserved in all members of the
Caliciviridae, yet the mechanism of its synthesis is poorly under-
stood. In contrast, the synthesis of sgRNA is well characterized in
numerous other RNA viruses (reviewed in reference 14). For vi-
ruses that possess only a single genomic RNA and generate a single
sgRNA, one commonly used mechanism for sgRNA synthesis is
the premature termination of negative-strand RNA synthesis that
is used by the viral replicase as a template to produce the positive-
sense sgRNA. A hallmark of the premature termination mecha-
nism is the production of a truncated negative-sense sgRNA dur-
ing virus replication. Low levels of negative-sense sgRNA have
been identified in cells stably replicating the Norwalk virus repli-
con (29), in purified replication complex from feline calicivirus-
infected cells (28), and as now in MNV-infected cells (Fig. 8).
However, our data and those from previous publications (15)
suggest an alternative model for MNV sgRNA synthesis. This
mechanism is used by plant viruses (23, 30, 31) and alphavi-
ruses (32, 33) and involves the binding of the viral replicase
complex to a specific sequence and/or structure present in neg-
ative-sense genomic RNA. Our data are consistent with Sla5045
being required as an RNA structure needed for MNV infectivity
and to function as a template for RNA synthesis by the RdRp. It
is also important to note that in the plant viruses, it is not clear
which subunit(s) of the viral replicase can specifically recog-
nized the sgRNA promoter, and our results demonstrate that
the norovirus RdRp is sufficient for recognition of the sgRNA
core promoter. In addition we observed that a genotype-spe-
cific interaction between the RdRp and the subgenomic pro-
script affected the amount of RNA synthesis (Fig. 7D). Our
data would, however, indicate that as negative-sense sgRNA is
present in MNV-infected cells, the newly synthesized MNV
sgRNA may function as a template for additional rounds of
RNA replication by the viral RdRp via a double-stranded RNA
(dsRNA) intermediate.
The precise initiation site of the calicivirus sgRNA has been
identified previously in a number of studies. The human norovi-
rus sgRNA initiation site has been previously confirmed using a
helper virus system to drive the production of viral genomic RNA
in cells (34). In the related vesivirus FCV, 5= RACE was also used to
FIG8 Negative-sense subgenomic RNA is produced during MNV replication.
(A) Northern blot analysis of RNA isolated from either mock-infected (mock)
or MNV-infected (Inf) cells. A 1.5-g portion of RNA harvested 10 h postin-
fection of cells with a multiplicity of infection of 5 TCID50 per cell was dena-
tured by glyoxylation prior to agarose gel electrophoresis. Positive- and nega-
tive-sense RNAs were detected using strand-specific RNA probes as described
in Materials and Methods. Control in vitro-transcribed RNAs representing the
positive-sense () or negative-sense () viral RNAs were used as a control.
(B). Quantitative real-time PCR analysis of the RNA sample shown in panel A.
The RNA was analyzed using a strand-specific RT-qPCR assay designed to
detect only the genomic RNA or both genomic and subgenomic RNAs simul-
taneously. The genome copy number is shown as genome equivalents per 25 ng
of total RNA and was determined by comparison to in vitro-transcribed con-
trol RNAs. The data shown represent the mean and standard deviation from 4
independent repeats.
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identify the specific sgRNA initiation site (35). To our knowledge,
our work provides the first confirmation of the start site of noro-
virus sgRNA during an authentic infectious norovirus replication
cycle.
Our data indicate that the positioning of the core sgRNA
promoter is critical for its function, as in the Sla5045Dup con-
structs, only the sgRNA promoter sequences in Sla2 region
functioned (Fig. 5). In addition, increasing the distance be-
tween the stem-loop structure and the sgRNA initiation site
from 6 to 8 nt also debilitated virus replication (Fig. 6). These
data are in agreement with our previous observations using
bioinformatics analysis of all calicivirus genomes that indicate
an absolute conservation of the spacing, i.e., invariably 6 nt
(16).
Overall our data demonstrate that norovirus sgRNA synthe-
sis relies on a sequence- and genotype-specific interaction of
the viral RdRp with a stem-loop sequence on the minus-strand
RNA. These observations add to our growing understanding of
the norovirus life cycle and the molecular mechanisms used by
caliciviruses to control viral genome translation and replica-
tion.
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